Lamotrigine XR Conversion to Monotherapy: First Study Using a Historical Control Group

Neurotherapeutics

Volumn 9, Issue 1, 2012, Pages 176-184

  French, Jacqueline A ^a   Temkin, Nancy R ^b   Shneker, Bassel F ^c   Hammer, Anne E ^d   Caldwell, Paul T ^d   Messenheimer, John A ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Clinical trial; epilepsy; Historical controls; Lamotrigine; Monotherapy; Partial epilepsy; Seizures

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG WITHDRAWAL; FOCAL EPILEPSY; HUMAN; INSOMNIA; MONOTHERAPY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 84856611764     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0088-3     Document Type: Article

References (15)

1. Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs 2008; 22: 917-938.
2. Sachdeo R. Monotherapy clinical trial design. Neurology 2007; 69(24 suppl 3): S23-S27.
3. Gilliam FG. Limitations of monotherapy trials in epilepsy. Neurology 2003; 60(suppl 4): S26-S30.
4. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000; 133: 455-463.
5. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsy 1991; 32: 716-721.
6. Declaration of Helsinki. Tokyo: World Medical Association, 2004, October 9.
7. French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 2010; 51: 1936-1943.
8. Baulac M. Historical data in the design and interpretation of trials with newly diagnosed patients. Epilepsy Res 2006; 68: 77-81.
9. Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology 2003; 60(suppl 4): S13-S25.
10. Gilliam F, Vazquez B, Sackellares et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018-1025.
11. Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002; 59: 79-83.
12. Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011, Sept 19 [Epub ahead of print].
13. Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011; 52: 219-233.
14. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Peripheral and Central Nervous System Drugs Advisory Committee meeting. March 10, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria ls/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM2504 89. pdf. Accessed May 5, 2011.
15. Marson AG, Al-Kharusi AM et al.; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.